Form4insider filings, from the source

SEC Form 4 · accession 0001567619-18-002676

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Sep 12, 2018
Accepted (ET)
Sep 14, 2018 · 6:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockSep 12, 2018M5,500$3.648A19,200D
Common StockF2,F3Sep 12, 2018S756$164.4383D18,444D
Common StockF2,F4Sep 12, 2018S1,885$165.3156D16,559D
Common StockF2,F5Sep 12, 2018S1,059$166.738D15,500D
Common StockF2,F6Sep 12, 2018S1,000$167.392D14,500D
Common StockF2,F7Sep 12, 2018S200$168.785D14,300D
Common StockF2,F8Sep 12, 2018S600$171.0267D13,700D
Common StockSep 13, 2018M4,500$3.648A18,200D
Common StockF2,F9Sep 13, 2018S2,700$165.4463D15,500D
Common StockF2,F10Sep 13, 2018S1,500$166.6347D14,000D
Common StockF2,F11Sep 13, 2018S300$167.4867D13,700D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F12$3.648Sep 12, 2018M5,500D—Jun 18, 2024Common Stock5,50062,769D
Employee Stock Option (Right to Buy)F12$3.648Sep 13, 2018M4,500D—Jun 18, 2024Common Stock4,50058,269D

Explanation of responses